DDDT-6627-identification-of-targets-and-new-developments-in-the-treatm

First Page		Document Content
Chemistry Multiple sclerosis Cytokines Autoimmune diseases Treatment of multiple sclerosis Cladribine Natalizumab Fingolimod Biogen Idec Medicine Immunology Immunosuppressants		DDDT-6627-identification-of-targets-and-new-developments-in-the-treatm Add to Reading List Source URL: www.ncbi.nlm.nih.gov Download Document from Source Website File Size: 232,01 KB Share Document on Facebook

	Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translatio DocID: 1qn6Z - View Document
	Stellungnahme der AkdÄ zur Nutzenbewertung von Fingolimod (neues Anwendungsgebiet) DocID: 1n48S - View Document
	Rote-Hand-Brief zu Gilenya® (Fingolimod) DocID: 1h06f - View Document
	Biotin (Cerenday) for permanent disability related to multiple sclerosis relapses – add on therapy to current immunomodulators DocID: 1fWCE - View Document
	Bijlage bij email betreffende vergoeding fingolimod juliArtikel uit MenSen nr. 4 Samenvatting aanvullende voorwaarden zoals is overeengekomen op 4 juni 2013 met CVZ, VWS, zorgverzekeraars, MS Vereniging Nederland, DocID: 1ea9n - View Document